Theranostics 2020; 10(26):11938-11949. doi:10.7150/thno.49451 This issue Cite

Research Paper

An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer

Silei Sui1,2#, Xin An2#, Caiming Xu3,4#, Zongjuan Li1#, Yijun Hua2, Geya Huang1, Sibei Sui5, Qian Long2, Yanxia Sui2, Yuqing Xiong6, Micheal Ntim7, Wei Guo1, Miao Chen2, Wuguo Deng1,2✉, Xiangsheng Xiao2✉, Man Li1✉

1. The Second Affiliated Hospital of Dalian Medical University; Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China.
2. Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
3. Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
4. Institute (College) of Integrative Medicine, Dalian Medical University, Dalian, China.
5. The First People's Hospital of Yichang (People's Hospital of Three Gorges University), Yichang, Hubei, China.
6. Vagelos College of Physicians and Surgeons, Columbia University, New York, USA.
7. Department of Physiology, Dalian Medical University, Dalian, China.
#These authors contributed equally to this article.

Citation:
Sui S, An X, Xu C, Li Z, Hua Y, Huang G, Sui S, Long Q, Sui Y, Xiong Y, Ntim M, Guo W, Chen M, Deng W, Xiao X, Li M. An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer. Theranostics 2020; 10(26):11938-11949. doi:10.7150/thno.49451. https://www.thno.org/v10p11938.htm
Other styles

File import instruction

Abstract

Graphic abstract

Background: Immune cells have essential auxiliary functions and influence clinical outcomes in cancer, with high immune infiltration being associated with improved clinical outcomes and better response to treatment in breast cancer (BC). However, studies to date have not fully considered the tumor-infiltrating immune cell (TIIC) landscape in tumors. This study investigated potential biomarkers based on TIICs to improve prognosis and treatment effect in BC.

Results: We enrolled 5112 patients for analysis and used cell type identification by estimating relative subsets of RNA transcripts (CIBERSORT), a new computational algorithm, to quantify 22 TIICs in primary BC. From the results of univariate Cox regression, 12 immune cells were determined to be significantly related to the overall survival (OS) of BC patients. Furthermore, least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analyses were applied to construct an immune prognostic model based on six potential biomarkers. By dividing patients into low- and high-risk groups, a significant distinction in OS was found in the training cohort, with 20-year survival rates of 42.6% and 26.3%, respectively. Applying a similar protocol to validation and test cohorts, we found that OS was significantly shorter in the high-risk group than in the low-risk group, regardless of the molecular subtype of BC. Using the immune score model to predict the effect of BC patients to chemotherapy, the survival advantage for the low-risk group was evident among those who received chemotherapy, regardless of the chemotherapy regimen. In evaluating the predictive value of the nomogram, a decision curve showed better predictive accuracy than the standard tumor-node-metastasis (TNM) staging system.

Conclusion: The immune cell infiltration-based immune score model can be effectively and efficiently used to predict the prognosis of BC patients as well as the effect of chemotherapy.

Keywords: tumor-infiltrating immune cells, breast cancer, CIBERSORT, immune score, prognostic


Citation styles

APA
Sui, S., An, X., Xu, C., Li, Z., Hua, Y., Huang, G., Sui, S., Long, Q., Sui, Y., Xiong, Y., Ntim, M., Guo, W., Chen, M., Deng, W., Xiao, X., Li, M. (2020). An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer. Theranostics, 10(26), 11938-11949. https://doi.org/10.7150/thno.49451.

ACS
Sui, S.; An, X.; Xu, C.; Li, Z.; Hua, Y.; Huang, G.; Sui, S.; Long, Q.; Sui, Y.; Xiong, Y.; Ntim, M.; Guo, W.; Chen, M.; Deng, W.; Xiao, X.; Li, M. An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer. Theranostics 2020, 10 (26), 11938-11949. DOI: 10.7150/thno.49451.

NLM
Sui S, An X, Xu C, Li Z, Hua Y, Huang G, Sui S, Long Q, Sui Y, Xiong Y, Ntim M, Guo W, Chen M, Deng W, Xiao X, Li M. An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer. Theranostics 2020; 10(26):11938-11949. doi:10.7150/thno.49451. https://www.thno.org/v10p11938.htm

CSE
Sui S, An X, Xu C, Li Z, Hua Y, Huang G, Sui S, Long Q, Sui Y, Xiong Y, Ntim M, Guo W, Chen M, Deng W, Xiao X, Li M. 2020. An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer. Theranostics. 10(26):11938-11949.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image